Concord Drugs

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE858L01010
NSEID:
BSEID: 538965
View on BSE

INR

72.00

-0.03 (-0.04%)

BSENSE

Mar 25

BSE+NSE Vol: 7.62 k

{
  "main_header": {
    "sid": 605306,
    "name": "Concord Drugs",
    "stock_name": "Concord Drugs",
    "full_name": "Concord Drugs Ltd",
    "name_url": "stocks-analysis/concord-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "72.00",
    "chg": -0.03,
    "chgp": "-0.04%",
    "dir": -1,
    "prev_price": "72.03",
    "mcapval": "75.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 538965,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE858L01010",
    "curr_date": "Mar 25",
    "curr_time": "",
    "bse_nse_vol": "7.62 k",
    "exc_status": "Active",
    "traded_date": "Mar 25, 2026",
    "traded_date_str": "2026 03 25",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/concord-drugs-605306-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3893195",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ConcordDrugsLtd_mojoScore_3893195.png",
        "date": "2026-03-16 10:10:31",
        "description": "Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Concord Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-downgraded-to-sell-amid-mixed-financial-and-technical-signals-3852284",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ConcordDrugsLtd_mojoScore_3852284.png",
        "date": "2026-02-24 08:11:12",
        "description": "Concord Drugs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 23 February 2026. This shift reflects a complex interplay of deteriorating technical indicators, subdued financial performance, and valuation adjustments, despite the company’s long-term market outperformance. Investors should carefully consider these factors amid the stock’s recent 5% decline and evolving market dynamics."
      },
      {
        "title": "Concord Drugs Declines 0.78%: Valuation Upgrade and Mixed Fundamentals Shape Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-drugs-declines-078-valuation-upgrade-and-mixed-fundamentals-shape-week-3849834",
        "imagepath": "",
        "date": "2026-02-21 16:04:25",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>16 Feb:</strong> Q3 FY26 results released showing revenue growth but margin pressure</p>\n                    <p><strong>19 Feb:</strong> Investment rating upgraded to Hold on improved valuation and market performance</p>\n                    <p><strong>19 Feb:</strong> Valuation grade shifted to Attractive despite recent share price dip</p>\n                    <p><strong>20 Feb:</strong> Week closes at Rs.84.45, down 0.78% for the week versus Sensex +0.39%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.85.11</div></div>\n                    <div class=\"st..."
      },
      {
        "title": "Concord Drugs Ltd Upgraded to Hold on Attractive Valuation and Market Performance",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-upgraded-to-hold-on-attractive-valuation-and-market-performance-3846409",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ConcordDrugsLtd_mojoScore_3846409.png",
        "date": "2026-02-19 08:08:04",
        "description": "Concord Drugs Ltd has seen its investment rating upgraded from Sell to Hold, driven primarily by an improved valuation outlook and robust market performance. Despite flat recent financial results, the company’s attractive valuation metrics, solid return ratios, and strong one-year stock returns have prompted analysts to revise their stance, signalling cautious optimism for investors."
      },
      {
        "title": "Concord Drugs Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-drugs-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-3846232",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ConcordDrugsLtd_valuationdot_3846232.png",
        "date": "2026-02-19 08:00:58",
        "description": "Concord Drugs Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating despite a strikingly high price-to-earnings (P/E) ratio of 143.09. This recalibration reflects evolving market perceptions and comparative metrics within the Pharmaceuticals & Biotechnology sector, offering investors a nuanced perspective on the stock’s price attractiveness relative to its peers and historical benchmarks."
      },
      {
        "title": "Concord Drugs Q3 FY26: Revenue Surge Masks Margin Pressure",
        "link": "https://www.marketsmojo.com/news/result-analysis/concord-drugs-q3-fy26-revenue-surge-masks-margin-pressure-3842706",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ConcordDrugs_quaterlyResult_3842706.png",
        "date": "2026-02-16 12:43:03",
        "description": "Concord Drugs Ltd., a Telangana-based pharmaceutical manufacturer specialising in injectable formulations and finished dosage forms, reported mixed results for Q3 FY26 (October-December 2025), with net profit declining 4.35% year-on-year to ₹0.22 crores despite a robust 57.31% surge in net sales. The company's stock, trading at ₹84.05 with a market capitalisation of ₹84.05 crores, has delivered exceptional returns of 144.33% over the past year but faces mounting concerns over profitability erosion and operational efficiency."
      },
      {
        "title": "Are Concord Drugs Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-concord-drugs-ltd-latest-results-good-or-bad-3840347",
        "imagepath": "",
        "date": "2026-02-14 19:40:31",
        "description": "Concord Drugs Ltd's latest financial results for the quarter ending September 2025 present a mixed picture. The company reported net sales of ₹10.28 crores, which reflects a year-on-year decline of 16.90%. This marks the lowest quarterly sales figure in the past seven quarters, indicating potential challenges in demand and competitive positioning within the pharmaceutical sector. The sequential performance also shows a significant contraction of 24.47% from the previous quarter, suggesting volatility in revenue generation.\n\nOn the profitability front, Concord Drugs achieved a net profit of ₹0.19 crores, representing a substantial year-on-year growth of 375.00%. This improvement in net profit is accompanied by a notable expansion in operating margins, which increased to 10.70% from 7.04% in the same quarter last year. This margin expansion indicates effective cost management and operational efficiency, even ..."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-3830427",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ConcordDrugsLtd_mojoScore_3830427.png",
        "date": "2026-02-10 10:10:48",
        "description": "Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 11 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 February 2026, providing investors with the most up-to-date insight into the company’s performance and outlook."
      },
      {
        "title": "When is the next results date for Concord Drugs Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-concord-drugs-ltd-3819128",
        "imagepath": "",
        "date": "2026-02-03 23:16:55",
        "description": "The next results date for Concord Drugs Ltd is scheduled for 14 February 2026...."
      }
    ],
    "total": 272,
    "sid": "605306",
    "stock_news_url": "https://www.marketsmojo.com/news/concord-drugs-605306"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "17-Feb-2026",
      "details": "News Paper publication of Q3 results",
      "source": "BSE"
    },
    {
      "caption": "General Update",
      "datetime": "16-Feb-2026",
      "details": "General Update",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Out Come Of Board Meetings",
      "datetime": "14-Feb-2026",
      "details": "Board of Directors approved financial results for 31 st December2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Concord Drugs Ltd is Rated Sell

2026-03-16 10:10:31

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Concord Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals

2026-02-24 08:11:12

Concord Drugs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 23 February 2026. This shift reflects a complex interplay of deteriorating technical indicators, subdued financial performance, and valuation adjustments, despite the company’s long-term market outperformance. Investors should carefully consider these factors amid the stock’s recent 5% decline and evolving market dynamics.

Read full news article

Concord Drugs Declines 0.78%: Valuation Upgrade and Mixed Fundamentals Shape Week

2026-02-21 16:04:25

Key Events This Week

16 Feb: Q3 FY26 results released showing revenue growth but margin pressure

19 Feb: Investment rating upgraded to Hold on improved valuation and market performance

19 Feb: Valuation grade shifted to Attractive despite recent share price dip

20 Feb: Week closes at Rs.84.45, down 0.78% for the week versus Sensex +0.39%

Week Open

Rs.85.11

Read full news article

Concord Drugs Ltd Upgraded to Hold on Attractive Valuation and Market Performance

2026-02-19 08:08:04

Concord Drugs Ltd has seen its investment rating upgraded from Sell to Hold, driven primarily by an improved valuation outlook and robust market performance. Despite flat recent financial results, the company’s attractive valuation metrics, solid return ratios, and strong one-year stock returns have prompted analysts to revise their stance, signalling cautious optimism for investors.

Read full news article

Concord Drugs Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges

2026-02-19 08:00:58

Concord Drugs Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating despite a strikingly high price-to-earnings (P/E) ratio of 143.09. This recalibration reflects evolving market perceptions and comparative metrics within the Pharmaceuticals & Biotechnology sector, offering investors a nuanced perspective on the stock’s price attractiveness relative to its peers and historical benchmarks.

Read full news article

Concord Drugs Q3 FY26: Revenue Surge Masks Margin Pressure

2026-02-16 12:43:03

Concord Drugs Ltd., a Telangana-based pharmaceutical manufacturer specialising in injectable formulations and finished dosage forms, reported mixed results for Q3 FY26 (October-December 2025), with net profit declining 4.35% year-on-year to ₹0.22 crores despite a robust 57.31% surge in net sales. The company's stock, trading at ₹84.05 with a market capitalisation of ₹84.05 crores, has delivered exceptional returns of 144.33% over the past year but faces mounting concerns over profitability erosion and operational efficiency.

Read full news article

Are Concord Drugs Ltd latest results good or bad?

2026-02-14 19:40:31

Concord Drugs Ltd's latest financial results for the quarter ending September 2025 present a mixed picture. The company reported net sales of ₹10.28 crores, which reflects a year-on-year decline of 16.90%. This marks the lowest quarterly sales figure in the past seven quarters, indicating potential challenges in demand and competitive positioning within the pharmaceutical sector. The sequential performance also shows a significant contraction of 24.47% from the previous quarter, suggesting volatility in revenue generation. On the profitability front, Concord Drugs achieved a net profit of ₹0.19 crores, representing a substantial year-on-year growth of 375.00%. This improvement in net profit is accompanied by a notable expansion in operating margins, which increased to 10.70% from 7.04% in the same quarter last year. This margin expansion indicates effective cost management and operational efficiency, even ...

Read full news article

Concord Drugs Ltd is Rated Sell

2026-02-10 10:10:48

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 11 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 February 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.